President and CEO, AirXpanders
Stories naming Scott Dodson. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
ASX-listed medical device maker AirXpanders, based in California, released its 2017 full-year results, reporting growing AeroForm sales, a US$34 million equity placement, and a US$15 million debt facility with Oxford Finance.
US-based medical device maker AirXpanders, listed on the ASX, proposes adding Liz Hammack to its board as co-founder Teddy Shalon departs and fellow director Dennis Condon faces re-election at its May annual meeting.
AirXpanders wins US regulator clearance for an improved film material in its breast reconstruction device, reporting sales hires and clinic conversions as its American rollout begins ahead of schedule.
A breast reconstruction device maker presented its needle-free tissue expansion technology at a Barcelona surgical conference, where a US trial investigator shared results and the chief executive outlined plans for European availability.
ASX-listed medical device maker AirXpanders, based in California, has committed investors for a A$45 million private placement at A$0.92 per CDI, with Canaccord Genuity as sole lead manager, to fund its US commercial launch.
Also GBS Ventures·GBS Ventures
Breast reconstruction device maker AirXpanders gained US regulator clearance for its needle-free AeroForm tissue expander, enabling a January 2017 American launch; an amended CE Mark also covers an enhanced version.
AirXpanders shared new clinical data for its AeroForm breast reconstruction device at a major plastic surgery meeting, showing faster expansion times, and an Australian study author received a best-paper award.
ASX-listed breast reconstruction device maker AirXpanders secured commitments for a 20 million dollar placement at 76 cents per CDI, and appointed Scott Murcray CFO/COO ahead of its planned US launch.
AirXpanders reported positive results from its XPAND pivotal trial of the AeroForm tissue expander at a major plastic surgery meeting, showing faster expansion than saline devices, as it seeks US FDA clearance.
AirXpanders reports brisk early adoption of its AeroForm tissue expander after its Australian launch, citing surgeon training, hospital onboarding, and steps toward a US market entry.
AirXpanders' needle-free breast-reconstruction device is showcased at a major American plastic surgery conference, with trial results presented; the ASX-listed company awaits a US regulatory decision.
Also GBS Ventures·GBS Ventures
Breast reconstruction device maker AirXpanders has lodged a 510(k) regulatory submission with US authorities for its needle-free AeroForm tissue expander, following positive clinical trial results, as it moves toward entering the American market.
ASX-listed breast reconstruction device maker AirXpanders reports its pivotal XPAND trial met its primary endpoint, with results to go to the US regulator and be presented at a plastic surgery meeting in Boston.